We previously reported the short-term outcomes of SBRT for PSMA detected oligometastatic prostate cancer[4] and demonstrated very high rates of local control, but the majority of our cohort had failed biochemically by 18months. This evidence concerns the gene FOLH1 and prostate carcinoma.